Ligand Pharma (LGND) Reiterated at Buy by Stifel After Chat With CEO, CFO
Tweet Send to a Friend
Stifel analyst Annabel Samimy reiterated a Buy rating and $332.00 price target on Ligand Pharma (NASDAQ: LGND).The analyst commented, "At ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
